Download PDF
Thromb Haemost 2006; 95(02): 212-220
DOI: 10.1160/TH05-08-0550
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)

Manfred Rieger   *
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Silvia Ferrari   *
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Johanna A. Kremer Hovinga
2   Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
,
Christian Konetschny
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Andrea Herzog
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Letizia Koller
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Alfred Weber
3   Baxter BioScience, Department of Preclinical Research and Development, Vienna, Austria
,
Giuseppe Remuzzi
4   Mario Negri Institute for Pharmacological Research, and Division of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy
,
Michael Dockal
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Barbara Plaimauer
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
,
Friedrich Scheiflinger
1   Baxter Bioscience, Department of Discovery Research, Vienna, Austria
› Author AffiliationsFinancial support: This work was in part supported bya grant from Telethon (Grant No. GGPO2162) to GR.
Further Information

Publication History

Received 10 August 2005

Accepted after revision 08 January 2005

Publication Date:
28 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

We have established a new, enzyme-linked immunosorbent assay (ELISA) for the detection of ADAMTS13 antigen using purified polyclonal rabbit anti-human ADAMTS13 IgG. Normal plasma ADAMTS13 antigen levels span a concentration of 740 –1420ng/ml (median 1080ng/ml) resulting in an ADAMTS13 activity to antigen ratio of 0.48 to 1.68 U/µg. In a cohort of HUS patients, ADAMTS13 antigen was in the normal range, whereas in hereditary TTP patients antigen levels were low to undetectable, in concordance with severe deficient ADAMTS13 activity. Plasma of acquired TTP patients was found to contain free as well as autoantibody-bound ADAMTS13. We also present evidence for circulating anti-ADAMTS13 antibody/ADAMTS13 antigen immune complexes not only in acutely ill or actively treated patients but also in patients who have already achieved clinical remission. This new developed ADAMTS13 antigen ELISA assay allows rapid determination of ADAMTS13 antigen levels in human plasma but is of limited predictive value for the diagnosis or treatment of acquired TTP due to the detection of ADAMTS13 in antibody complexes.

Keywords

ADAMTS13 - ADAMTS13-antigen - ELISA - TTP - HUS

* Denotes equal contribution of S. F and M. R.


 

  • References

  • 1 Moake JL, Turner NA, Stathopoulos NA. et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 1456-61.
    CrossrefPubMedGoogle Scholar
  • 2 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
    PubMedGoogle Scholar
  • 3 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
    PubMedGoogle Scholar
  • 4 Gerritsen HE, Robles R, Lämmle B. et al. Partial amino acid sequence of purified von Willebrand factorcleaving protease. Blood 2001; 98: 1654-61.
    CrossrefPubMedGoogle Scholar
  • 5 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
    CrossrefPubMedGoogle Scholar
  • 6 Zheng X, Chung D, Takayama TK. et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276: 41059-63.
    CrossrefPubMedGoogle Scholar
  • 7 Soejima K, Mimura N, Hirashima M. et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem 2001; 130: 475-80.
    CrossrefPubMedGoogle Scholar
  • 8 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
    CrossrefPubMedGoogle Scholar
  • 9 Porter S, Clark IM, Kevorkian L. et al. The ADAMTS metalloproteinases. Biochem J 2005; 386: 15-27.
    CrossrefPubMedGoogle Scholar
  • 10 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
    CrossrefPubMedGoogle Scholar
  • 11 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
    PubMedGoogle Scholar
  • 12 Furlan M, Robles R, Solenthaler M. et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
    PubMedGoogle Scholar
  • 13 Furlan M, Robles R, Galbusera M. et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
    CrossrefPubMedGoogle Scholar
  • 14 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235-44.
    PubMedGoogle Scholar
  • 15 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
    CrossrefPubMedGoogle Scholar
  • 16 Remuzzi G, Galbusera M, Noris M. et al. Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002; 100: 778-85.
    CrossrefPubMedGoogle Scholar
  • 17 Remuzzi G. Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. J Thromb Haemost 2003; 01: 632-4.
    CrossrefPubMedGoogle Scholar
  • 18 Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
    CrossrefPubMedGoogle Scholar
  • 19 Manuelian T, Hellwage J, Meri S. et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-90.
    CrossrefPubMedGoogle Scholar
  • 20 Caprioli J, Castelletti F, Bucchioni S. et al. International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-95.
    CrossrefPubMedGoogle Scholar
  • 21 Noris M, Brioschi S, Caprioli J. et al. International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-7.
    CrossrefPubMedGoogle Scholar
  • 22 Raife T, Atkinson B, Montgomery R. et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of Thrombotic microangiopathy patients. Transfusion 2004; 44: 146-50.
    CrossrefPubMedGoogle Scholar
  • 23 Veyradier A, Girma JP. Assays of ADAMTS-13 activity. Semin Hematol 2004; 41: 41-7.
    CrossrefPubMedGoogle Scholar
  • 24 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (VWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Studt JD, Böhm M, Budde U. et al. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003; 01: 1882-7.
    CrossrefPubMedGoogle Scholar
  • 26 Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hemato 2002; 81: 430-5.
    PubMedGoogle Scholar
  • 27 Scheiflinger F, Knobl P, Trattner B. et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 3241-3.
    CrossrefPubMedGoogle Scholar
  • 28 Rieger M, Mannucci PM, Hovinga JA. et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262-7.
    CrossrefPubMedGoogle Scholar
  • 29 Plaimauer B, Zimmermann K, Volkel D. et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 2002; 100: 3626-32.
    CrossrefPubMedGoogle Scholar
  • 30 Food and Drug Administration and Center for Veterinary Medicine. Guidance for industry. Validation of analytical procedures: Methodology. VICH GL2, October 1998
    PubMedGoogle Scholar
  • 31 Findlay JW, Smith WC, Lee JW. et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000; 21: 1249-73.
    CrossrefPubMedGoogle Scholar
  • 32 Klaus C, Plaimauer B, Studt JD. et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004; 103: 4514-9.
    CrossrefPubMedGoogle Scholar
  • 33 Crawley J, Lam J, Rance J. et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 1085-93.
    PubMedGoogle Scholar
  • 34 Zheng X, Nishio K, Majerus EM. et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003; 278: 30136-41.
    CrossrefPubMedGoogle Scholar
  • 35 Soejima K, Matsumoto M, Kokame K. et al. ADAMTS13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003; 102: 3232-7.
    CrossrefPubMedGoogle Scholar